SWT012 / Sidewinder Therapeutics - LARVOL DELTA

OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates (FierceBiotech) - "Sidewinder’s signature approach is a bispecific antibody-drug conjugate technique, which the company is developing for solid tumors....The series B brings Sidewinder’s total haul to $162 million....The biotech plans to file an investigational new drug application for its lead asset, SWT012, by the end of 2026, according to a corporate presentation shared with Fierce Biotech. SWT012 has been tested in animal models of bladder cancer, the presentation said, while other bispecifics, SWT019 and SWT020, have been preclinically tested in lung cancer and colorectal cancer, respectively. An IND application for SWT019 and the selection of a final formulation of SWT020 are set to follow in the first half of 2027."

Financing • IND • Preclinical • Bladder Cancer • Colorectal Cancer • Non Small Cell Lung Cancer